Core Viewpoint - The company, HeartFlow Medical-B (02160), is experiencing a decline in stock price ahead of its mid-year performance announcement, with a projected net loss for the first half of 2025 not exceeding RMB 10 million, representing a year-on-year decrease of at least 83% [1] Financial Performance - The company anticipates a significant reduction in net loss due to increased sales of the VitaFlow Liberty transcatheter aortic valve and delivery system in over 20 countries/regions, with overseas revenue more than doubling [1] - The commercial progress of the AnchorMan left atrial appendage occluder system and its guiding system in China is steady, and it has received CE marking for commercialization in Europe, contributing to revenue growth [1] Operational Efficiency - Continuous optimization of resource allocation has further enhanced operational efficiency [1] - The completion of D-round financing by the joint venture 4C Medical has resulted in a decrease in the company's shareholding, which is recognized as a gain from the sale of equity [1]

《从治疗到预防养护:移动式雾化护眼的场景体验创新》 14:10-14:30 徐亿,雾以希总裁 | 大会嘉宾 眼未来|思宇MedTech 本文包括： 参会注意事项、会议完整议程，请转发给参会的朋友。 有效报名的同志们，都已收到了拉群邀约 ，请一定入群。大会云相册、会刊、午餐事项等，都在群中 （没有入群的朋友，请主动添加微信号suribot22） ▍大会总体议程 | | 开幕式(全球眼科大会+全球生物医药大会) | | --- | --- | | 时间 | 主题与嘉宾 | | 9:00-9:10 | 致辞坏节: | | | 林航,海淀区副区长 | | | 刘慧,北京医药健康科技发展中心主任 | | | 任秋实,北京大学未来技术学院生物医学工程系教授,国 家杰青,长江学者,美国生物与医学工程学会会士、国际 | | | 光学学会会士 | | 9 : 10-9 : 11 | 《2025全球眼科创新年度白皮书》 &数据发布 | | 9:11-9:13 | 全球眼科创新大奖颁布 | | 9 : 13-9 : 15 | 中关村联新生物医药产业联盟会员授牌 | | 9:15-9:30 | 《北京市支持创新医药高质量发展若干措施 ...